PGEN Quote, Financials, Valuation and Earnings

GeoVax Labs, Inc. has a net margin of -5008.35% compared to Precigen, Inc.'s net margin of -630.04%. Precigen, Inc.'s return on equity of -711.28% beat GeoVax Labs, Inc.'s return on equity of -433.69%.

Precigen, Inc. has a consensus price target of $8.50, signalling upside risk potential of 104.33%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $9.63 which suggests that it could grow by 5217.68%. Given that GeoVax Labs, Inc. has higher upside potential than Precigen, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Precigen, Inc..

Precigen, Inc. has a beta of 1.162, which suggesting that the stock is 16.189% more volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.638, suggesting its more volatile than the S&P 500 by 263.848%.

Precigen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precigen, Inc. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.

Precigen, Inc. quarterly revenues are $2.9M, which are larger than GeoVax Labs, Inc. quarterly revenues of --. Precigen, Inc.'s net income of -$146.3M is lower than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Precigen, Inc.'s price-to-earnings ratio is -- while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precigen, Inc. is 196.22x versus 0.78x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Marker Therapeutics, Inc. has a net margin of -5008.35% compared to Precigen, Inc.'s net margin of -162.11%. Precigen, Inc.'s return on equity of -711.28% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.

Precigen, Inc. has a consensus price target of $8.50, signalling upside risk potential of 104.33%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.33 which suggests that it could grow by 411.03%. Given that Marker Therapeutics, Inc. has higher upside potential than Precigen, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Precigen, Inc..

Precigen, Inc. has a beta of 1.162, which suggesting that the stock is 16.189% more volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.977%.

Precigen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precigen, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.

Precigen, Inc. quarterly revenues are $2.9M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Precigen, Inc.'s net income of -$146.3M is lower than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Precigen, Inc.'s price-to-earnings ratio is -- while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precigen, Inc. is 196.22x versus 3.89x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Omeros Corp. has a net margin of -5008.35% compared to Precigen, Inc.'s net margin of --. Precigen, Inc.'s return on equity of -711.28% beat Omeros Corp.'s return on equity of --.

Precigen, Inc. has a consensus price target of $8.50, signalling upside risk potential of 104.33%. On the other hand Omeros Corp. has an analysts' consensus of $28.00 which suggests that it could grow by 78.23%. Given that Precigen, Inc. has higher upside potential than Omeros Corp., analysts believe Precigen, Inc. is more attractive than Omeros Corp..

Precigen, Inc. has a beta of 1.162, which suggesting that the stock is 16.189% more volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.485, suggesting its more volatile than the S&P 500 by 148.518%.

Precigen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precigen, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.

Precigen, Inc. quarterly revenues are $2.9M, which are larger than Omeros Corp. quarterly revenues of --. Precigen, Inc.'s net income of -$146.3M is lower than Omeros Corp.'s net income of -$21.2M. Notably, Precigen, Inc.'s price-to-earnings ratio is -- while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precigen, Inc. is 196.22x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Vistagen Therapeutics, Inc. has a net margin of -5008.35% compared to Precigen, Inc.'s net margin of -7525.97%. Precigen, Inc.'s return on equity of -711.28% beat Vistagen Therapeutics, Inc.'s return on equity of -76.57%.

Precigen, Inc. has a consensus price target of $8.50, signalling upside risk potential of 104.33%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $0.97 which suggests that it could grow by 32.71%. Given that Precigen, Inc. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe Precigen, Inc. is more attractive than Vistagen Therapeutics, Inc..

Precigen, Inc. has a beta of 1.162, which suggesting that the stock is 16.189% more volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.86%.

Precigen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precigen, Inc. pays -- of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend.

Precigen, Inc. quarterly revenues are $2.9M, which are larger than Vistagen Therapeutics, Inc. quarterly revenues of $258K. Precigen, Inc.'s net income of -$146.3M is lower than Vistagen Therapeutics, Inc.'s net income of -$19.4M. Notably, Precigen, Inc.'s price-to-earnings ratio is -- while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precigen, Inc. is 196.22x versus 25.57x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.